Pilot of Adalimumab Withdrawal

Project Period:

Grant Category:
Large Grant

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Adalimumab (Humira) is the most used biologic used to treat juvenile idiopathic arthritis (JIA). Stopping adalimumab is a priority for many patients and families. We do not yet know how best to get patients off adalimumab or who can safely stop without flaring. While a randomized trial would help us learn how to stop adalimumab and who should or should not stop, we do not yet have enough information to start such a trial. For this reason, we propose the Pilot of Adalimumab Withdrawal (PAW). PAW will test 30 participants with JIA as they taper or stop adalimumab and 1-2 months later to see if they can collect blood samples at home. We will use small devices that collect blood from a fingerstick to see whether they are useful and acceptable to patients and families. This study represents a partnership among pediatric rheumatologists, laboratory scientists, and parent-scientists.


Daniel B. Horton, MD, MSCE

Rutgers Robert Wood Johnson Medical School

Related Awarded Grants